Revenue: As of FY2025 Q3, the actual value is USD 9.812 M.EPS: As of FY2025 Q3, the actual value is USD 0.82.EBIT: As of FY2025 Q3, the actual value is USD 1.892 M.<h3>Segment Revenue</h3><ul><li>Labor &amp; Delivery: $1,039 in 3Q 2025, $3,089 in 9M 2025.</li><li>Gynecology/Electrosurgery/Urology: $4,954 in 3Q 2025, $14,656 in 9M 2025.</li><li>Neonatal: $2,176 in 3Q 2025, $6,261 in 9M 2025.</li><li>Blood Pressure Monitoring and Accessories: $1,643 in 3Q 2025, $5,469 in 9M 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $2,631 in 3Q 2025, $8,720 in 9M 2025, representing a decrease of 26.2% and 20.5% respectively compared to the same periods in 2024.</li><li>Gross Margin: 57.1% in 3Q 2025, 56.8% in 9M 2025, down from 58.0% and 59.3% in the respective periods of 2024.</li><li>Operating Income: $2,611 in 3Q 2025, $8,961 in 9M 2025, reflecting a decline of 21.9% and 16.0% respectively from 2024.</li><li>Operating Margin: 26.6% in 3Q 2025, 30.4% in 9M 2025, compared to 33.4% and 33.6% in the same periods of 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $11,215 in 9M 2025, compared to $11,894 in 9M 2024.</li><li>Free Cash Flow: Not explicitly stated, but net cash used in financing activities was $10,367 in 9M 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Adjusted EBITDA: $4,170 in 3Q 2025, $13,493 in 9M 2025, showing a decrease of 15.9% and 12.7% respectively from 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: UTMD plans to introduce high-pressure process control transducer configurations to biopharmaceutical manufacturers and continue leveraging OUS distribution and manufacturing synergies.</li><li>Non-Core Business: The company remains vigilant for affordable accretive acquisition opportunities and plans to utilize positive cash generation for dividends and share repurchases.</li><li>Priority: Management expects 2025 revenues to be 6-7% lower than 2024, with EPS projected in the range of $3.40-3.50.</li></ul>

Utah Medical Products | 10-Q: FY2025 Q3 Revenue: USD 9.812 M